Personalis Receives New Order From the VA’s Million Veteran Program – Total Contracted Now Almost 80,000 Whole Human Genomes
MENLO PARK, Calif.--(BUSINESS WIRE)--Oct 9, 2018--Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced an extension to their contract with the US Department of Veterans Affairs (VA) to sequence a further 34,000 whole human genomes for the VA’s Million Veteran Program (MVP). This brings the total of all Personalis contracts from the MVP to almost 80,000 human genomes.
Personalis was awarded its first contract with the VA MVP in 2012. Since then, Personalis has heavily invested in technology and infrastructure to expand its high-volume capabilities. Personalis CEO, John West, said, “Personalis’ business with the VA is well aligned with our growing immuno-oncology business: efficient high-quality scaling to many tens of thousands of samples is important to both. There is also good alignment in the scale of assays and informatics between these. Our work for the VA MVP is now all at the whole genome level and in immuno-oncology we are also innovating at the high end with extremely deep whole-exome-scale cell-free DNA analysis, as one example.”
About the VA Million Veteran Program (MVP)
Launched in 2011, MVP is a landmark research effort aimed at better understanding how genetic variations affect health. Up to a million Veterans are expected to enroll in the VA study by 2021. Data and genetic samples collected through the program are stored securely and made available for studies by authorized researchers, with stringent safeguards in place to protect Veterans’ private health information. MVP is now enrolling at 63 VA medical centers nationwide. The VA’s central biorepository is equipped with a state-of-the-art robotic system for DNA extraction and storage and is currently being expanded to support up to 4 million samples. With about 700,000 enrollees to date, MVP already far exceeds the enrollment numbers of any single VA study or research program in the past, and is in fact one of the largest research cohorts of its kind in the world.
MVP provides researchers with a rich resource of genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses. By combining this information into a single database, MVP promises to advance knowledge about the complex links between genes and health.
Veterans’ privacy and confidentiality are top priorities in MVP, as in all VA research. For more information about MVP, visit www.research.va.gov/MVP.
This press release does not imply a Department of Veterans Affairs endorsement, and is neither paid for nor sponsored, in whole or in part, by any element of the United States Government.
About Personalis, Inc.
Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005458/en/
CONTACT: Personalis, Inc.
Jennifer Havlek, 650-752-1300
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY DEFENSE OTHER DEFENSE RESEARCH SCIENCE
SOURCE: Personalis, Inc.
Copyright Business Wire 2018.
PUB: 10/09/2018 11:00 AM/DISC: 10/09/2018 11:01 AM